We Have a New Treatment, But You Can't Afford It

Author: Christopher E. Desch MD
View More View Less

Christopher E. Desch, MD, is the National Medical Director of the NCCN and Co-Editor-in-Chief of JNCCN. As National Medical Director, Dr. Desch serves as the clinical leader for the broad spectrum of NCCN programs, including the NCCN Clinical Practice Guidelines in Oncology™. Dr. Desch previously served as hematologist/oncologist and Research Director for Virginia Cancer Institute. He is Chair of the Health Services Committee at the American Society of Clinical Oncology and has been a member of the American College of Physicians, the American Society of Hematology, and the Virginia Society of Hematology/Oncology.

  • 1.

    Motzer RJ, Michaelson MD, Redman BG et al.. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:1624.

    • Search Google Scholar
    • Export Citation
  • 2.

    Pfizer Oncology. Sutent (sunitinib malate) capsules US fact sheet. Available at: http://www.pfizer.com/pfizer/download/news/asco/sutent_fact_sheet.pdf. Accessed June 26, 2006.

    • Search Google Scholar
    • Export Citation
  • 3.

    American Cancer Society. Medicare Part D: what you need to know about the new drug benefit. Available at: http://www.cancer.org/docroot/MIT/MIT_3_1_Medicare_Part_D.asp. Accessed June 26, 2006.

    • Search Google Scholar
    • Export Citation
  • 4.

    McGivney W. Coverage policy and use beyond the FDA-approved label. J Natl Compr Canc Netw 2006;4:99101.

  • 5.

    Sutent. Resources for health care professionals. Available at: http://www.sutent.com/content/Sutent_P1_Resources_HCP.jsp. Accessed June 26, 2006.

    • Search Google Scholar
    • Export Citation
  • 6.

    Szabo L. Price of cancer drugs called ``mind-boggling'' [USA Today Web site]. July 22, 2004. Available at:http://www.keepmedia.com/pubs/USATODAY/2004/07/22/512271?extID=10037&oliID=229. Accessed June 29, 2006.

    • Search Google Scholar
    • Export Citation
  • 7.

    Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002;360:711715.

    • Search Google Scholar
    • Export Citation
  • 8.

    Hillner BE, Smith TJ, Desch CE. Principles of cost effectiveness analysis for the assessment of current and new therapies. J Hematother 1993;2:501506.

    • Search Google Scholar
    • Export Citation
  • 9.

    Norum J, Risberg T, Olsen JA. A monoclonal antibody against HER-2 (traztuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol 2005;16:909914.

    • Search Google Scholar
    • Export Citation
  • 10.

    Mayor S. NICE approves traztuzumab for early stage breast cancer. BMJ 2006;332:14091413.

  • 11.

    Alexander G, Casalino L, Meltzer D. Patient-physician communication about out-of-pocket costs. JAMA 2003;290:25432544.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 35 16 1
PDF Downloads 41 16 2
EPUB Downloads 0 0 0